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ABSTRACT
Ovarian toxicity (ovotoxicity) is one of the major side effects of pharmaceutical
compounds for women at or before reproductive age. The current gold standard for
screening of compounds for ovotoxicity largely relies on preclinical investigations using
whole animals. However, in vivo models are time-consuming, costly, and harmful to
animals. Here, we developed a three-tiered ovotoxicity screening approach starting from
encapsulated in vitro follicle growth (eIVFG) and screened for the potential ovotoxicity
of 8 preclinical compounds from AstraZeneca (AZ). Results from Tier 1 and 2 screenings
using eIVFG showed that the first 7 tested AZ compounds, AZ-A, -B, -C, -D, -E, -F, and
-G, had no effect on examined mouse follicle and oocyte reproductive outcomes,
including follicle survival and development, 17β-estradiol (E2) secretion, ovulation, and
oocyte meiotic maturation. However, AZ-H, a preclinical compound targeting the
checkpoint kinase 1 (Chk1) inhibitor to potentiate the anticancer effects of DNAdamaging agents, significantly promoted granulosa cell apoptosis and the entire growing
follicle atresia at clinically-relevant concentrations of 1 and 10 μM. The more targeted
explorations in Tier 2 revealed that the ovotoxic effect of AZ-H primarily resulted from
Chk1 inhibition in granulosa cells. Using in vivo animal models, the Tier 3 screening
confirmed the in vitro ovotoxicities of AZ-H discovered in Tiers 1 and 2. Using in vivo
mouse model, the Tier 3 screening confirmed the in vitro ovotoxicities of AZ-H
discovered in Tiers 1 and 2. Also, although AZ-H at 0.1 μM alone was not ovotoxic, it
significantly exacerbated gemcitabine-induced ovotoxicities on growing follicles. Taken
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together, this study demonstrates that the tiered ovotoxicity screening approach starting
from eIVFG identifies and prioritizes chemicals of high ovotoxicity concern.
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CHAPTER 1
INTRODUCTION
The research and development (R&D) of new drugs is an extremely complex and
expensive process. On average, it costs about $2.6 billion and more than 10 years for a
new drug to be developed from its initial discovery to marketing approval (DiMasi et al.,
2016). Of all the candidate compounds, approximately only 0.1% of them are able to pass
preclinical evaluations for clinical trials, and 0.01-0.02% of them will receive final
approval from the Food and Drug Administration (FDA) (Bakke et al., 1995; Eisenstein
et al., 2005; Wong et al., 2019). Of all the failed compounds, more than 50% of them
exhibit unintended toxicities to the tested cells, animals, and healthy volunteers or
patients (Waring et al., 2015). Furthermore, post-market safety monitoring results in a
withdrawal of 1 - 4% of all marketed drugs for safety concerns (Bakke et al., 1995;
Onakpoya et al., 2016; Siramshetty et al., 2016; Wysowski & Swartz, 2005). Female
reproductive toxicity is one of the major side effects of pharmaceutical compounds,
particularly for the childhood, adolescent, and young adult populations, who are within or
will be in reproductive age. However, the majority of recruited healthy volunteers or
patients in clinical trials are adult males to protect the limited ovarian reserve and also
avoid potential pregnancy in females (Gynecologists, 2015), so the evaluation of
potential side effects of different compounds on female reproductive system relies largely
on preclinical investigations using whole animals.
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The ovary is the primary female reproductive organ and functions to synthesize
and secrete sex steroid hormones and to mature and ovulate germ cell oocyte for
fertilization and pregnancy. Increasing evidence demonstrates that a broad spectrum of
pharmaceutical compounds and environmental chemicals can result in female ovarian
toxicity (ovotoxicity) and increase women’s risks of premature ovarian failure (POF),
hormonal imbalance, and sub- or in-fertility (Bhattacharya & Keating, 2012; Vabre et al.,
2017). In contrast to other organ systems in which toxic chemical exposure typically
causes subclinical phenotypes or development of overt diseases, predicting the impact of
chemicals on the ovary is difficult and can be overlooked for an extended period of time
until attempts are made to conceive, or the genetic or epigenetic defects of gametes are
discovered in subsequent generation(s).
Thus far, the lack of optimal in vitro models makes the gold standard for
preclinical testing of the ovotoxicity of chemicals rely primarily on whole laboratory
animals. However, in vivo models are time- and effort-consuming and costly, and it is
also unethical to sacrifice a large number of animals for human benefits. Moreover, the
U.S. FDA guideline using whole animals to detect female reproductive toxicity of
pharmaceuticals requires examining the estrous cycle and litter size as well as some overt
disease phenotypes such as miscarriage, teratogenicity, and infertility (FDA, 2017).
However, the specific upstream reproductive endpoints in the ovary, such as follicle
development, hormone secretion, and oocyte maturation and ovulation, are equally
important, yet difficult to monitor in real time without dissecting whole animals. Ovarian
cell lines including both follicular somatic cells (e.g. granulosa cell lines) and denuded
oocytes have been cultured in vitro for testing chemicals’ ovotoxicity (Havelock et al.,
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2004; Pocar et al., 2003, 2001). For example, the SV40 transformed cell lines, granulosa
cell lines, are used for studying the molecular events regulating granulosa cell
steroidogenesis, including expressing follicle stimulating hormone receptors (Keren-Tal
et al., 1993). However, the three-dimensional (3D) cell/tissue specific architecture is
missing in these cultures. More importantly, normal follicle development and oocyte
maturation require orchestrated bidirectional communications between somatic cells and
their enclosed oocyte (Biggers et al., 1967; Buccione et al., 1990; Eppig et al., 2005; Gui
& Joyce, 2005; Su et al., 2008). For example, the granulosa cells transfer metabolic
products such as amino acids, pyruvate, and cholesterol to oocytes through gap junctions
to promote oocyte maturation (Biggers et al., 1967; Eppig et al., 2005; Su et al., 2008); in
turn, the oocyte-secreted factors such as growth differentiation factor 9 (GDF9) and bone
morphogenetic protein 15 (BMP15) control granulosa cell metabolism and differentiation
(Buccione et al., 1990; Gui & Joyce, 2005). These facts indicate that for the lack of
physical contacts and biochemical crosstalks between somatic cells and oocytes (Chen et
al., 2013; Gilchrist et al., 2006; Matzuk et al., 2002; Su et al., 2009; Sugiura et al., 2005),
the traditional cultures of individual type of ovarian cells cannot reconstitute the
physiology necessary for testing the ovitoxicity of chemical exposure as with intact
ovaries or follicles in vivo.
The method of in vitro ovarian follicle culture has been used for examining the
effect of xenobiotic exposures on female ovarian function, suggesting a robust model for
in vitro ovotoxicity testing (Rasmussen et al., 2017; Stefansdottir et al. 2014; Wang et al.,
2018; Xiao, Zhang, et al., 2017a; Zhou & Flaws, 2017; Zhou et al., 2015; Zhou &
Shikanov, 2018). In our previous studies, we have used the alginate hydrogel
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encapsulation method to culture both mouse and human preantral follicles in vitro (Xiao,
Duncan, et al., 2015; Xiao, Zhang, et al., 2015; Xiao, Zhang, et al., 2017b), which is
termed encapsulated in vitro follicle growth (eIVFG). The eIVFG maintains the 3D
architecture of follicles and recapitulates most of key events of folliculogenesis and
oogenesis in vivo, including follicle growth and development from the primary or
secondary stage to antral stage for maturation, hormone secretion, and oocyte maturation
and ovulation (Table 1.1). In the present study, we further developed a novel tiered
ovotoxicity screening approach starting from eIVFG and screened for the potential
ovotoxicity of 8 preclinical compounds from AstraZeneca (AZ). The in vivo or clinically
relevant exposure concentrations were used, which were determined based on the in vivo
pharmacokinetic data in various species (e.g. mouse, rat, and dog) from AZ or previously
published results. In summary, our results indicate that the tiered ovotoxicity screening
approach allows us to identify and prioritize chemicals of high ovotoxicity concern for
more targeted, sophisticated, and mechanistic evaluations.
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Table 1.1 The eIVFG maintains the 3D architecture of follicles and recapitulates most of
key events of folliculogenesis and oogenesis in vivo
In vivo model
Folliculogenesis
and oogenesis

Follicle growth
and development
from the primary
or secondary
stage antral stage
for maturation
Ovulation

Gonadotropin
regulation

Steroidogenesis

Fertilization

Implantation of
embryos

Live birth
outcomes

Hormone
secretion:
estradiol,
androstenedione,
and progesterone

eIVFG
Follicle grows when maintains architecture
and the spatial relationship of the oocyte and
its supporting somatic cells (Kreeger et al.,
2006; Xiao, Duncan, et al., 2015; Xiao,
Zhang, et al., 2015; Xu, Barrett, et al., 2009;
Xu et al., 2006).
During in vitro maturation, hydrogelencapsulated follicles develop mature
oocytes within the capacity for fertilization
which is similar to that of oocytes matured in
vivo. (Kreeger et al., 2006; Xiao, Duncan, et
al., 2015; Xiao, Zhang, et al., 2015; Xu et al.,
2006).
Gonadotropin supplement with adequate
concentration is performed to support the
hormonal and environmental needs of the
follicle culture (Kreeger et al., 2005; Xu et
al., 2011).
The hormone secretion patterns are similar to
in vivo model (Kreeger et al., 2006;
Songsasen et al., 2011; Xiao, Duncan, et al.,
2015; Xiao, Zhang, et al., 2015; Xu et al.,
2011; Xu, Barrett, et al., 2009; Xu et al.,
2006; Xu, West-Farrell, et al., 2009).
Oocytes undergo successful in vitro
fertilization, and produce implantable
zygotes that develop into viable, fertile
offspring. Nevertheless, in vitro–cultured
oocytes which were successfully fertilized is
fewer than in vivo oocytes (Xu et al., 2006).
Embryos derived from cultured oocytes
fertilized in vitro and transferred to
pseudopregnant female mice were viable (Xu
et al., 2006).
Mice derived from oocytes cultured in
vitro developed normally. Both male and
female offspring were fertile. But the live
birth rate remains low in the mouse (Xu et
al., 2006).
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CHAPTER 2
METHODS
Methodologies used for identifying pharmaceutical compounds with high
ovotoxicity concern, including materials for lab experiments, and all statistical analyses
performed in the study are outlined in the Chapter 2.
2.1 Animals
The CD-1 mouse breeding colony (Charles River Laboratory, Wilmington, MA)
was maintained in the animal facility at the University of South Carolina. All mice were
housed in polypropylene cages and provided with food and water ad libitum. Animals
were kept on a 12-hour light/dark cycle (7:00 AM to 7:00 PM) at 23±1°C with 30-50%
relative humidity. All methods used in this study were approved by the University of
South Carolina Institutional Animal Care and Use Committee (IACUC) and
corresponded to the National Institutes of Health (NIH) guidelines and public law.
2.2 Follicle isolation, encapsulation, and culture
Immature ovarian follicles at multilayered secondary stage (150-180 μm, type 5b)
were mechanically isolated from 15- or 16-day-old CD-1 female mice as we previously
described (Xiao, Duncan, et al., 2015; Xiao, Zhang, et al., 2017a). Only follicles that
displayed intact morphology were selected for encapsulation and culture. Selected
follicles were encapsulated individually in 0.5% alginate hydrogel (Sigma-Aldrich, St.
Louis, MO, USA). Follicles were placed in maintenance media containing minimal
essential medium (αMEM with Glutamax, Gibco, Thermo Fisher Scientific Inc.,
6

Waltham, MA, USA) and 1% fetal bovine serum (FBS, Sigma-Aldrich) for 0.5 hour (hr)
after encapsulation. Encapsulated follicles were then individually placed in 96-well
plates, with each well containing 100 μl growth media (50% αMEM with Glutamax and
50% Nutrient Mixture [F-12 with Glutamax, Gibco, Thermo Fisher Scientific Inc.]
supplemented with 3 mg/ml bovine serum albumin [BSA, Thermo Fisher Scientific Inc.],
20 mIU/ml recombinant follicle-stimulating hormone [rFSH, A. F. Parlow, National
Hormone and Peptide Program, National Institute of Diabetes and Digestive and Kidney
Diseases, Bethesda, MD, USA], 1 mg/ml bovine fetuin [Sigma-Aldrich], 5 μg/ml insulin,
5 μg/ml transferrin, and 5 ng/ml selenium [ITS, Sigma-Aldrich]). Follicles were cultured
at 37°C in 5% CO2 for 8 days and half of the growth media (50 µl) was replaced every
other day. For all experiments, follicles were randomly distributed to experimental
groups with each group having 8-12 follicles and 3-5 replicates were performed.
2.3 Follicle growth and survival assessment
Follicles cultured using eIVFG were imaged at each media change using an
Olympus CKX53 Inverted Microscope with 10x and 20x objectives (Olympus
Corporation, Hachioji-shi, Tokyo, Japan). Follicles were considered dead if they had
unhealthy appearing oocytes and/or granulosa cells, or if the integrity of the oocyte and
somatic cell interface was visibly compromised. Follicle growth curves were obtained by
plotting the average follicle diameter, which was calculated by averaging two
perpendicular measurements from basement membrane to basement membrane of each
follicle using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Follicle survival rate was calculated by dividing the number of survived follicles on days
0, 2, 4, 6, and 8 to the number of cultured follicles on day 0. For each experimental
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group, the follicle growth curve and survival rates on days 0, 2, 4, 6, 8 were plotted, and
the lethal concentration 50 (LC50) on in vitro cultured follicles was calculated using
global nonlinear regression (dose-response curve) which is a four-parameter logistic
function via GraphPad Prism (GraphPad Software, San Diego, CA, USA).
2.4 Hormone measurements
The 17β-estradiol (E2) concentrations in the conditioned follicle culture media on
day 8 of eIVFG were collected and measured using ELISA kits (Calbiotech, Spring
Valley, CA, USA) according to the manufacturer’s instructions. Briefly, the anti-estradiol
capture antibodies pre-coated wells were incubated with E2 standards, conditioned
follicle culture media, and Estradiol Biotin Reagent for 45 minutes (min). Next, the
Estradiol Enzyme Reagent was added and incubated for another 45 min. After washing
the wells with the washing buffer for three times, the solution of TMB reagent was added
and incubated at room temperature for 20 min, resulting in the development of blue color.
Last, the reaction was stopped by the addition of Stop Solution and the absorbance was
measured using a BioTek Synergy HT microplate reader (BioTek Instruments, Inc.,
Winooski, VT, USA) at 450 nm within 15 min. All assays were run in duplicate.
2.5 In vitro ovulation, oocyte maturation, and oocyte size measurement
On day 8 of eIVFG, follicles were mechanically removed from alginate beads and
then incubated in in vitro maturation media (αMEM with 10% FBS, 1.5 IU/ml human
chorionic gonadotropin [hCG, Sigma-Aldrich], and 10 ng/ml epidermal growth factor
[EGF; from R&D Systems, Minneapolis, MN, USA]) for 16 hr at 37°C in 5% CO2 in air.
Oocytes were denuded from surrounding cumulus cells using 0.3% hyaluronidase
(Sigma-Aldrich). Oocytes were considered to be arrested at prophase I in the germinal

8

vesicle (GV) stage if the nucleus was intact, and were considered to have undergone
germinal vesicle breakdown (GVBD) if the nucleus was not visible. If a polar body was
present in the perivitelline space, the oocytes were classified as metaphase II (MII).
Fragmented or shrunken oocytes were classified as degenerated (D). For all MII oocytes,
the oocyte diameter was obtained from two perpendicular measurements, including the
zona pellucida. The first measurement detected the widest diameter of oocyte and the
second measurement originated at a right angle from the midpoint of the first
measurement. The final oocyte diameter was calculated by averaging the two obtained
measurements.
2.6 AZ compound exposure and ovotoxicity testing
All 8 tested pharmaceutical compounds were kindly gifted from AZ (Cambridge,
United Kingdom) from projects that closed because of non-female reproductive toxicity
safety reasons identified during preclinical or clinical development. Because the Material
Transfer Agreement (MTA) with AZ, we named them from AZ-A to AZ-H instead of
using their original AZ library IDs. However, for the compounds of AZ-A and AZ-H that
are commercially available now for scientific research, we started to use their original AZ
library IDs (AZD8542 for AZ-A and AZD7762 for AZ-H) and also introduced their
molecular target from the Tier 2 screening. All tested AZ compounds were dissolved in
100% dimethyl sulfoxide (DMSO, Sigma-Aldrich) to make a stock concentration at 200
mM and the stock solutions were stored at -20°C and away from light. For ovotoxicity
testing, the stock solutions were diluted to the targeted exposure concentrations in follicle
culture media. In Tier 1 ovotoxicity screening, follicles were treated with each tested
candidate compound at 10 M from day 2 to day 8 of eIVFG. We started compound
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exposure from day 2 instead day 0 to exclude any dead follicles within the first 2 days of
eIVFG that might have resulted from mechanical manipulation during follicle isolation.
In Tier 2 ovotoxicity screening, follicles were treated with AZ-A as the negative control
and AZ-H as the positive control at 0, 0.1, 1, and 10 M for 24 hours from day 2 of
eIVFG, followed by a continuous culture without AZ compound until day 8 of eIVFG.
The rationale for determining in vitro compound exposure concentrations was described
in the Results section. For both Tier 1 and Tier 2 screenings, the assessments of follicle
and oocyte reproductive outcomes were performed as described above, including follicle
survival, follicle development, E2 secretion, and in vitro ovulation and oocyte
maturation.
2.7 Chk1 or Chk2 inhibitor treatment and ovotoxicity testing
Another set of multilayered secondary follicles were isolated and cultured using
eIVFG. Follicles were treated with three specific Chk1 inhibitors, including Rabusertib at
2 μM, CHIR-124 at 0.2 μM, and MK-8776 at 20 μM, and one Chk2 inhibitor, BML-277
at 5 μM from day 2 to day 8 of eIVFG. The follicle survival and development were
examined as described above. The concentrations we used were either based on human
plasma/serum levels in clinical trials or based on previous results that showed effective
checkpoint kinase inhibition in in vitro cultured cell lines. The detailed justification was
described in the Results section.
2.8 In vivo animal exposure
In order to investigate whether the gained ovotoxicities of AZ-H in Tier 1 and 2
screenings could be validated using in vivo animal models, 21-day-old CD-1 female mice
were intraperitoneally injected with 25 mg/kg of AZ-H dissolved in 50 μl DMSO. We
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used 21-day-old mice because their ovaries contain all developmental stages of preantral
and antral follicles, indicating a good in vivo animal model to study the impact of
xenobiotic exposure on female ovarian functions (Y. Wang et al., 2019a; Y. Wang et al.,
2018). The same volume of DMSO was used as the vehicle control. AZ-A that showed
negative ovotoxicity in Tiers 1 and 2 screenings was used as negative control and the
exposure dose of AZ-A was at 20 mg/kg through intraperitoneal injection. The rationale
of the in vivo dose selection for both AZ-A and AZ-H was described in the Results
section. Ovaries were collected 24 hr post-injection for histology and TUNEL staining.
2.9 Gemcitabine and doxorubicin treatment
Follicles were treated with different concentrations of gemcitabine (GEM, SigmaAldrich) at 0, 0.02, 0.1, and 0.5 μM and doxorubicin (DOX, Sigma-Aldrich) at 0, 10, 20,
and 50 nM alone or with AZ-H at 0.1 μM for 24 hr, followed by a continuous culture
using compound-free growth media until day 8 of eIVFG. The follicle and oocyte
reproductive outcomes were assessed as described above, including follicle survival and
follicle development. The specific rationale of using GEM and DOX for co-treatment
experiments and determination of concentration range were described in the Results
section.
2.10 Histology and TUNEL assay
For in vitro exposure experiments, follicles were collected at 24 hr after vehicle or
AZ compound treatment and fixed overnight at 4°C in 4% PFA-Cacodylate-Ca2+ Fixation
Buffer (4% paraformaldehyde [PFA; Sigma-Aldrich], 0.1 M Sodium Cacodylate
[Electron Microscopy Sciences, Hatfield, PA, USA], 0.1 M Sucrose [Sigma-Aldrich], 10
mM Calcium chloride [CaCl2; Thermo Fisher Scientific Inc.], pH=7.4). After washing
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with 1× phosphate-buffered saline (PBS, Thermo Fisher Scientific Inc.) three times, fixed
follicles were dehydrated in ascending concentrations of ethanol (50%-100%) and
embedded in paraffin (Sigma-Aldrich). For in vivo exposure experiments, ovaries were
collected 24 hr after vehicle or AZ compound injection, fixed in ShandonTM FormalFixxTM 10% Neutral Buffered Formalin solution (ThermoFisher Scientific Inc.) for 24 hr,
and embedded in paraffin. Both embedded follicles and ovaries were sectioned at the
thickness of 5 μm with a RM 2165 microtome (Leica Microsystems, Nussloch,
Germany). For histology staining, paraffin sections of follicles or ovaries were stained
with hematoxylin and eosin (H&E, Thermo Fisher Scientific Inc.) as we previously
described (Xiao, Duncan, et al., 2015). The DeadEndTM Fluorometric TUNEL System Kit
(Promega, Madison, WI, USA) was used to detect apoptotic cells according to the
manufacturer’s instructions. Briefly, paraffin sections of follicles or ovaries were
deparaffinized, rehydrated, and fixed in 4% formaldehyde in 1× PBS. After
permeabilizing by 20 g/ml Proteinase K solution for 10 min, the TdT reaction mix was
added to the ovarian/follicular sections and incubated for 1 hr at 37°C in a humidified
chamber. The sections were counter-stained using Vectashield Mounting Medium with
DAPI (Vector Laboratories, Burlingame, CA, USA) and TUNEL positive signals were
analyzed under Olympus BX51 microscope (Olympus Corporation, Hachioji-shi, Tokyo,
Japan) and quantified by ImageJ software. The relative TUNEL fluorescence intensity
was calculated according to the following formula: intensity = total TUNEL positive
signal pixel intensity / area.
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2.11 Statistical analyses
Follicle growth, survival, hormone secretion, and oocyte reproductive outcomes
were analyzed from 3 independent cultures in which 8-12 follicles were included in each
experimental group and replicate. Follicle growth pattern and survival rates on the same
day, hormone secretion on day 8, ovulated MII oocyte percentage and diameter, and
TUNEL positive signal in different drug-treated groups were analyzed using one-way
ANOVA. The post hoc test was performed to compare the difference between two groups
if a significant difference was observed. The significance level was set at P < 0.05.
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CHAPTER 3
RESULTS
3.1 The development of a tiered ovotoxicity screening
To efficiently and effectively identify and prioritize pharmaceutical compounds of
high ovotoxicity concerns for more advanced assessments, we developed a tiered
ovotoxicity screening starting from eIVFG (Figure 3.1). In Tier 1, follicles were treated
with each candidate compound at a single high dose from day 2 to day 8 of eIVFG.
During the entire compound exposure window, the follicle and oocyte reproductive
outcomes were evaluated, including follicle survival, follicle growth and development,
sex steroid hormone secretion, and in vitro ovulation and oocyte maturation. If no
ovotoxic outcome was discovered, the tested compound would be identified as having no
ovotoxicity concern. In contrast, if any adverse readouts were detected, the candidate
compound would be considered as a suspect ovotoxic chemical and advanced to Tier 2
screening with more sophisticated testing, such as the dose-response expsoure, specific
window exposure, or more in-depth cellular or molecular targeted toxicity investigations.
The specific experimental design in Tier 2 was dependant on the ovotoxicity results
obtained in Tier 1. For compounds that exhibited negative ovotoxic outcomes in Tier 2,
they would be reconsidered as low ovotoxicity concern. However, if the tested
compounds showed consistent ovotoxicities between Tier 1 and 2, we would further
advance them to Tier 3 screening with in vivo animal exposure and toxicity validation. If
a tested compound shows consistent ovotoxicities in all three tiers, it was identified as an
14

ovotoxic chemical. If a compound showed inconsistent ovotoxicities between in vitro and
in vivo models, more factors would be considered and investigated, such as liver
metabolism, pharmacokinetics/toxicokinetics, local or systemic effects.
3.2 Effects of AZ compounds on follicle survival, development, and hormone
secretion in Tier 1 screening
We used 8 AZ compounds (AZ-A to AZ-H) to test the performance of the
developed tiered ovotoxicity screening as described in Figure 3.1. Based on our internal
pharmacokinetic results in various species and published data, the majority of tested
compounds had the maximum plasma or serum concentrations up to 10 M. In the Tier 1
screening, we therefore treated cultured follicles with each candidate compound at a high
concentration at 10 M from day 2 to day 8 of eIVFG. In the control group, the alginate
hydrogel encapsulation maintained the 3D architecture of cultured follicles and supported
follicle growth from multilayered secondary stage on day 0 to antral stage on day 8
during eIVFG (Figure 3.2A). The follicle diameter increased from 161.9 ± 15.3 μm on
day 0 to 405.4 ± 28.4 μm on day 8, and the follicle survival rate was 100% on day 8
(Figure 3.2A). Follicles treated with all 8 AZ compounds at 10 M except AZ-H showed
comparable follicle survival rates and growth patterns to the control group (Figure 3.2A
and 2B). However, follicles treated with AZ-H at 10 M resulted in 100% follicle death
starting from day 4 of eIVFG (Figure 3.2A-2C).
To investigate the effects of AZ compounds on ovarian steroidogenesis, we
collected conditioned follicle culture media on day 8 and measured the concentration of
E2, an important sex steroid hormone synthesized and secreted from growing follicles
that supports the functions of ovary/follicles, downstream reproductive organs, and
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systemic health (Buyuk et al., 2010). ELISA results indicated that there were no
significant difference in the E2 secretion levels between control group and follicles
treated with all tested AZ compounds except AZ-H (Figure 3.3). The extremely low
concentrations of E2 in AZ-H treatment group reflected the above findings that all treated
follicles were dead on day 8. These results indicated that there was a low ovotoxicity
concern for the AZ compounds of AZ-A, AZ-B, AZ-C, AZ-D, AZ-E, AZ-F, and AZ-G.
However, AZ-H had suspected ovotoxicity and requires further investigations.
3.3 Effects of AZ compounds on follicle ovulation and oocyte meiotic maturation in
Tier 1 screening
We next treated grown antral follicles with hCG on day 8 to determine the effect
of AZ compound exposure during folliculogenesis and oogenesis on follicle ovulation
and oocyte meiotic maturation. Results showed that 88.9 ± 0.2% of antral follicles in the
control group ruptured and ovulated MII oocytes with the first polar body extrusion
(Figure 3.4A and 4B). The ovulated MII oocytes had normal morphological appearance
and the average MII oocyte diameter was 89.4 ± 3.5 μm (Figure 3.4C). Because there was
100% of follicle death on day 8 after AZ-H treatment (Figure 3.2), no follicle was
collected for in vitro ovulation and oocyte maturation (crosses in Figure 3.4B and 4C).
For the follicles treated with all the other 7 AZ-compounds, they had comparable
percentage of MII oocytes, morphological appearance, and oocyte size compared to the
control group (Figure 3.4), suggesting that these 7 AZ-compounds did not interfere with
follicle ovulation and oocyte meiotic maturation.
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3.4 Effects of AZ-H on follicle survival and development in Tier 2 screening
Based on the ovotoxicity screening results in Tier 1, we next selected the ovotoxic
compound AZ-H for a more advanced Tier 2 screening. We also chose AZ-A that did not
show ovotoxicity in Tier 1 as the negative control and used DMSO as the vehicle control.
AZ-A and AZ-H have the AZ compound library ID as AZD8542 and AZD7762 (so
referred to below), respectively. AZD8542 was designed as a hedgehog pathway
antagonist to inhibit tumor progression by targeting fibroblasts (Hwang et al., 2012); and
AZD7762 was designed as a checkpoint kinase 1 and 2 (Chk1/2) inhibitor to potentiate
the therapeutic effect of DNA damaging agents on tumor cells (Zabludoff et al., 2008).
Based on the results from previous clinical trials, the maximal plasma concentration of
AZD7762 was between 0.83-1.10 μM in humans (Sausville et al., 2014; Seto et al., 2013)
and 9 μM in dogs (unpublished data from AZ). Therefore, we performed a dose-response
study by treating cultured follicles at 0, 0.1, 1, and 10 μM in Tier 2. We also chose a
more specific exposure window by treating follicles for 24 hr because results from Tier 1
indicated that AZD7762 caused remarkable morphological changes to follicles within 24
hr (Figure 3.2C). For the compound of AZD8542, previous studies reported that the in
vitro treatment of AZD8542 at 0.1-1 μM effectively inhibited the hedgehog pathway in
human pancreatic stellate cells 24 hr after compound treatment (Hwang et al., 2012).
Therefore, we used the same exposure concentration range and window as the AZD7762.
Consistent to the ovotoxicity screening results in Tier 1, follicles treated with all
tested concentrations of AZD8542 had comparable follicle survival rates (Figure 3.5A,
left panel), follicle development patterns (Figure 3.5A, right panel), secreted E2 levels
(Figure 3.6A), and in vitro ovulation and oocyte meiotic division outcomes (Figure 3.6B)
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compared to the control group. However, for the follicles treated with AZD7762 at 1 or
10 M, all follicles were dead on day 4 or day 6 (Figure 3.5B and 5C) and the E2
secretion levels also significantly decreased on day 8 (Figure 3.6A). When follicles were
treated with AZD7762 at 0.1 M, the follicle survival rate and terminal diameter on day 8
decreased by 9.9% and 10.4%, respectively, compared to the control group, but the
changes were not statistically significant (Figure 3.5B). At the exposure concentration of
0.1 M, both the E2 secretion levels and MII oocyte percentages after in vitro ovulation
were comparable to the control group (Figure 3.6). These results indicated that Tier 1 and
Tier 2 screenings had consistent results and AZD7762 exhibits ovotoxicities when the
exposure level is at or higher than 1 M.
3.5 AZD7762 targeted granulosa cells to promote follicle atresia
We next selected the ovotoxic AZD7762 for more targeted histological staining
and TUNEL assay. DMSO was used as the vehicle control and AZD8542 was used as the
negative control. At 24 hr post-vehicle (DMSO) or 10 M AZD8542 treatment, follicles
had comparable morphology and TUNEL stainings to the control group (Figure 3.7A).
However, follicles treated with AZD7762 at 10 M showed markedly increased
granulosa cell apoptosis indicated by the DNA fragmentation in TUNEL staining (Figure
3.7A). Differing from some ovotoxic chemicals such as DOX that damage the outer
layers of the theca cells and granulosa cells and then promote the entire follicle atresia
(Xiao, Zhang, et al., 2017a), AZD7762 resulted in a greater degree of apoptosis in the
inner layers of the granulosa cells (Figure 3.7A). Moreover, up to 24 hr exposure of
AZD7762, TUNEL staining results indicated that the central oocytes did not show
obvious DNA damage compared to their surrounding somatic cells (Figure 3.7, white
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inserts). These data indicated that AZD7762 primarily targets inner granulosa cells to
promote the entire follicle atresia.
3.6 The inhibition of Chk1 but not Chk2 resulted in AZD7762-induced ovotoxicities
Since AZD7762 was found to have an equal inhibitory potency for Chk1 and
Chk2 (Ma et al., 2011; Morgan et al., 2010; Wang et al., 2018; Zabludoff et al., 2008), we
next treated follicles with more specific checkpoint kinase inhibitors to differentiate the
role of Chk1 and Chk2 in AZD7762-induced ovotoxicities. The tested inhibitors included
Chk1 inhibitors Rabusertib, CHIR-124, and MK-8776, and Chk2 inhibitor, BML-277.
The exposure concentrations were determined either based on human plasma/serum
levels for the cases of Rabusertib and MK-8776 (Karp et al., 2012; King et al., 2014;
Wang et al., 2014; Wehler et al., 2017) or based on previous in vitro studies that showed
effective checkpoint kinase inhibition in cultured cells for the cases of CHIR-124 and
BML-277 (Arienti et al., 2005; Boudny et al., 2019; Dai et al., 2011; Tse et al., 2007;
Tuppi et al., 2018). The ovotoxicity screening results revealed that all three tested Chk1
inhibitors exhibited similar ovotoxicities as AZD7762. Specifically, upon the treatment of
Rabusertib at 2 M, CHIR-124 at 0.2 M and MK-8776 at 20 M, the follicle survival
rates were decreased to 0, 25%, and 4%, respectively, on day 8 of eIVFG (Figure 3.7B
and 7C). Interestingly, follicles treated with the specific Chk2 inhibitor BML-277 at 5
M had comparable follicle survival rates and growth patterns to the control group
(Figure 3.7B and 7C). These results suggested that the inhibition of Chk1 but not Chk2
was responsible for the AZD7762-induced ovotoxicities on growing follicles.
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3.7 AZD7762 consistently promoted growing follicle atresia in vivo
To further validate the ovotoxicities of AZD7762 observed in Tiers 1 and 2
studies, we next performed in vivo animal exposure in Tier 3 screening. In previous
rodent models, animals were intravenously or intraperitoneally injected with AZD7762 at
10-25 mg/kg, which effectively potentiated chemotherapeutical drug-induced tumor cell
death (Itamochi et al., 2014; Ma et al., 2012; Quin et al., 2016; Zabludoff et al., 2008).
We therefore treated 21-day-old CD-1 female mice with AZD7762 at 25 mg/kg body
weight once. Meanwhile, DMSO was used as the vehicle control and AZD8542 as the
negative control. The treatment dose of AZD8542 was at 20 mg/kg which has been
demonstrated to significantly inhibit tumor growth in an in vivo colon cancer mouse
model (Hwang et al., 2012). Both histology and TUNEL staining of ovaries collected 24
hr after vehicle or AZ compounds injection indicated that AZD8542 treated ovaries had
similar ovary or follicle morphology and comparable levels of ovarian cell apoptosis
compared to the vehicle-treated ovaries (Figure 3.8). However, AZD7762 significantly
increased granulosa cell apoptosis in the secondary and antral stages of follicles, which
was characterized by the pyknotic and fragmented nuclei in histological staining (Figure
3.8A, black squares) and the DNA-fragmented nuclei in TUNEL staining (Figure 3.8A,
white squares). Similar to the in vitro ovotoxic patterns (Figure 3.7), in vivo results also
showed that AZD7762 caused a greater degree of cell apoptosis in the inner layers of the
granulosa cells compared to outer cell layers (Figure 3.8A, white squares). With respect
to the earlier stage of primordial follicles that we cannot examine using eIVFG, both
histological and TUNEL stainig results indicated that there was no significant difference
between all treatment groups (Figure 3.8A, red squares). These results indicated that the
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obtained ovotoxicities from eIVFG could be validated in in vivo animal models, and
AZD7762 primarily targeted growing follicles but not primordial follicles to result in
ovotoxicities.
3.8 AZD7762 exacerbated ovotoxicity of GEM but not DOX during eIVFG
Since AZD7762 was designed as a Chk1 inhibitor to enhance DNA-damaging
agent-induced cancer cell apoptosis (Zabludoff et al., 2008), we next determined whether
co-treatment with AZD7762 exacerbated chemodrug-induced ovotoxicities. We chose
GEM as the co-treated chemotherapeutic drug because it was used by most of previous
studies to test the synergistic anti-cancer effect of AZD7762 (Liu et al., 2017; Morgan et
al., 2010; Sausville et al., 2014; Seto et al., 2013; Zabludoff et al., 2008) and GEM has
also been reported to cause ovotoxicity by promoting growing follicle atresia (Yuksel et
al., 2015). Additionally, we tested the potential enhancing effect of AZD7762 on DOX,
another commonly used chemotherapeutic drug showing ovotoxicities on growing
follicles (Ben-Aharon et al., 2010; Roti Roti et al., 2012; Wang et al., 2019b; Xiao,
Zhang, et al., 2017a). Both GEM and DOX showed dose-dependent ovotoxicities on
cultured follicles during eIVFG as we and others previously demonstrated (Figure 3.9A
and 9B) (Xiao, Zhang, et al., 2017a; Yuksel et al., 2015). The treatment of AZD7762 at
0.1 M did not affect follicle development and survival (Figure 3.2); however, it
significantly promoted GEM-induced follicle atresia and inhibition of follicle growth and
development, particularly when GEM was at or above 0.1 M (Figure 3.9A). The LC50 of
GEM on follicle survival was 0.13 M (Figure 3.9C), however, it significantly decreased
to 0.04 M after follicles were co-treated with 0.1 M AZD7762 (Figure 3.9C).
Interestingly, both the follicle survival rates and follicle terminal diameters were similar
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between the DOX only and DOX and AZD7762 co-treatment groups (Figure 3.9B),
suggesting that there is no exacerbating effect of AZD7762 on DOX-induced ovotoxicity.
Taken together, these results indicated that the co-treatment of AZD7762 could
exacerbate chemotherapy-induced ovotoxicity, but the effect depended on the specific
anti-cancer agents, which have distinct cell-killing mechanisms.

Figure 3.1 The tiered ovotoxicity screening strategy for testing the effect of
pharmaceutical compounds on female reproductive health and fertility.
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Figure 3.2 Effect of 8 AZ compounds (AZ-A to AZ-H) on follicle survival and
development during encapsulated in vitro follicle growth (eIVFG). (A-B) Follicle
survival rates (A) and follicle diameters (B) during eIVFG after AZ compound exposure
at 10 M from day 2 to day 8. (C) Representative images of follicles during eIVFG
treated with vehicle or AZ-H at 10 M from day 2 to day 8. Error bar: standard deviation;
***p<0.001 compared to control group; scale bar: 100 μm. N=8-12 follicles in each
experimental group and three replicates were performed.
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Figure 3.3 Effect of 8 AZ compounds (AZ-A to AZ-H) on 17β-estradiol (E2) secretion on
day 8 of eIVFG. Error bar: standard deviation; ***p<0.001 compared to control group.
N=8-12 follicles in each experimental group and three replicates were performed.
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Figure 3.4 Effect of 8 AZ compounds (AZ-A to AZ-H) on in vitro ovulation and oocyte
meiotic maturation. (A) Representative images of a ruptured follicle (left) and ovulated
metaphase II (MII) oocyte (right) after treatment with human chorionic gonadotropin
(hCG) for 14 hours. (B-C) Oocyte MII percentages (B) and MII oocyte diameter (C) after
in vitro ovulation and oocyte maturation. Scale bar: 100 μm for ruptured follicle and 20
μm for MII oocyte; error bar: standard deviation. PB: polar body. The cross marks
indicated no follicles were selected for in vitro ovulation because of the 100% follicle
death upon AZ-H treatment. N=8-12 follicles in each experimental group and three
replicates were performed.
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Figure 3.5 Effect of AZD8542 and AZD7762 on follicle survival and development during
encapsulated in vitro follicle growth (eIVFG). (A-B) Follicle survival rates and follicle
diameters during eIVFG upon different concentrations of AZD8542 (A) and AZD7762
(B) treatment. (C) Representative images of follicles during eIVFG treated with
AZD7762 at 0, 0.1, 1 and 10 M for 24 hours (hr). Scale bar: 100 μm; error bar: standard
deviation; **p<0.01; ***p<0.001 compared to control group. N=8-12 follicles in each
experimental group
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Figure 3.6 Effect of AZD7762 and AZD8542 on 17β-estradiol (E2) secretion and oocyte
maturation in vitro. (A) E2 secretion levels on day 8 of eIVFG after follicles were treated
with different concentrations of AZD8542 and AZD7762 for 24 hr. (B) Oocyte
metaphase II (MII) percentages from follicles treated with different concentrations of
AZD8542 and AZD7762 for 24 hr. Error bar: standard deviation; ***p<0.001 compared
to control group. The cross marks indicated no follicles were selected for in vitro
ovulation because of the 100% follicle death upon AZ-H treatment. N=8-12 follicles in
each experimental group and three replicates were performed.
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Figure 3.7 Target inhibition of AZD7762 on ovarian follicle. (A) Representative images
of follicles in bright field and follicular cell apoptosis after follicles were treated with
AZD7762 and AZD8542 exposure at 10 M for 24 h in vitro. Blue: DAPI; green: DNA
fragmentation revealed by TUNEL staining. Scale bar: 100 μm. White squares indicated
the TUNEL staining of oocytes. N=5-10 follicles for each experimental group and three
replicates were performed. (B-C) Effect of three Chk1 inhibitors (Rabusertib at 2 μM,
CHIR-124 at 0.2 μM and MK-8776 at 20 μM) and one Chk2 inhibitor (BML-277 at 5
M) on follicle survival (B) and development (C) during encapsulated in vitro follicle
growth (eIVFG). Error bar: standard deviation; ***p<0.001 compared to control group.
N=8-12 follicles in each experimental group and three replicates were performed.
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Figure 3.8 Effect of AZD7762 and AZD8542 on ovarian follicle atresia in vivo. (A)
Representative ovary histological and TUNEL staining images 24 hours (hr) after
treatment of vehicle, AZD7762 at 25mg/kg, and AZD8542 at 20mg/kg through
intraperitoneal injection. Black squares indicated the histological staining of growing
follicles, white squares indicated the TUNEL staining of growing follicles, and red
squares indicated the TUNEL staining of primordial follicles. (B) Relative TUNEL
fluorescent intensity in the ovaries treated with vehicle, AZD7762, and AZD8542. Scale
bar: 100 μm. Error bar: standard deviation; **p<0.01. Blue: DAPI; green: DNA
fragmentation revealed by TUNEL staining. N=3-7 mice/ovaries in each treatment group.
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Figure 3.9 Effect of AZD7762 on exacerbating chemotherapeutic chemical-induced
ovotoxicity. (A-B) Follicle survival rates and terminal diameters on day 8 of eIVFG after
follicles were treated with gemcitabine (GEM) at 0, 0.02, 0.1 and 0.5 M (A) or
doxorubicin (DOX) at 0, 10, 20, and 50 nM (B) alone or co-treated with AZD7762 at 0.1
M. (C) Effect of different doses of chemicals on follicle survival and LC50 value for log
of concentration. Error bar: standard deviation; *p<0.05 and ***p<0.001 compared to
control group. N=8-10 follicles in each experimental group and three replicates were
performed.
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CHAPTER 4
DISCUSSION
Ovotoxicity is one of the major off-target effects of pharmaceutical compounds.
Previous studies have revealed that multiple drugs, such as chemotherapeutics, can
damage ovarian follicles and increase the risk of premature ovarian failure, early
menopause, and infertility in both reproductive aged women and prepubertal girls (Spears
et al., 2019). The current gold standard for ovotoxicity testing relies on whole laboratory
animals. However, it is challenging to use in vivo models to examine the specific and
dynamic follicle and oocyte reproductive outcomes without dissecting whole animals,
and it is also not feasible to use in vivo models to screen for the ovotoxicity of all
hundreds of even thousands of candidate compounds. Tiered screening strategies have
been increasingly employed in toxicity testing (Becker et al., 2007; Bus & Becker, 2009;
Doe et al., 2006; Krewski et al., 2010). Compared to traditional methods using whole
animals, the tiered screening is more efficient and cost-effective to identify and prioritize
chemicals of low or high toxicity concern for the following more targeted and
sophisticated assessments.
Previous studies have demonstrated that in vitro ovarian follicle culture is a robust
model for ovotoxicity testing (Rasmussen et al., 2017; Stefansdottir et al., 2014; Wang et
al., 2018; Xiao, Duncan, et al., 2015; Xiao, Zhang, et al., 2017a; Zhou & Flaws, 2017;
Zhou et al., 2015; Zhou & Shikanov, 2018). Here, we developed a tiered ovotoxicity
screening approach to identify pharmaceutical compounds of high ovotoxicity concern.
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The tiered screening begins with eIVFG in Tier 1, a 3D in vitro follicle growth method
we have previously developed (Xiao, Duncan, et al., 2015; Xiao, Zhang, et al., 2015;
Xiao, Zhang, et al., 2017b), as a highly sensitive but less sophisticated screening method.
If the tested compounds present negative ovotoxicities, they will be considered as low
ovotoxicity concern. In contrast, for compounds that do not pass Tier 1 screening, more
complex approaches will be used to further determine the likelihood and extent of the
potential ovotoxicity in the Tier 2 and 3 screenings. In addition, the results obtained in
Tier 1 will also be used to determine which specific tests should be conducted in Tier 2
and 3.
Our Tier 1 screening results showed that all the tested AZ compounds except
AZD7762 (AZ-H) had no impact on the follicle and oocyte health (Figure 3.2-4).
However, AZD7762 is a suspect ovotoxic chemical. In Tier 2, we chose AZD7762 with
suspicious ovotoxicity and AZD8542 with negative ovotoxicity for a more sophisticated
dose-response study and obtained consistent ovotoxic results (Figure 3.5-6). Specifically,
we found that AZD7762 primarily damages granulosa cells but not oocytes to induce the
entire follicle atresia (Figure 3.7A). Furthermore, we validated the positive and negative
ovotoxicities of AZD7762 and AZD8542, respectively, using in vivo animal models in
Tier 3 (Figure 3.8). These results suggest that eIVFG has a great potential to serve as an
effective and efficient in vitro model for identifying and prioritizing chemicals of high
ovotoxicity concern.
AZD7762 was originally designed as a selective ATP-competitive Chk1 inhibitor
to abrogate S or G2 phase checkpoints to enhance DNA-damaging agent-induced cancer
cell death, particularly for cancer cells that are deficient in the G1-DNA damage
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checkpoint due to Tp53 mutation (Zabludoff et al., 2008). It was later found that
AZD7762 also had an equal inhibiting potency on Chk2 (Ma et al., 2011; Morgan et al.,
2010; L. Wang et al., 2018; Zabludoff et al., 2008). Chk1 and Chk2 are serine/threonine
specific protein kinases and coordinate DNA damage response (DDR). When DNA
damage occurs during mitosis or upon genotoxic insults, ataxia telangiectasia-mutated
(ATM) and/or ATM and Rad3-related (ATR) are phosphorylated and activated
(Abraham, 2001; Yang et al., 2003), which in turn activate Chk2 and Chk1 through
phosphorylation (Reinhardt & Yaffe, 2009; Smith et al., 2010), respectively. The
activated ATM/Chk2 and/or ATR/Chk1 pathways further lead to Cdk1/2 inhibition
through Chk1/Chk2-dependent phosphorylation and degradation of Cdc25 (Falck et al.,
2001; Goto et al., 2019; Thanasoula et al., 2012), triggering cell cycle arrest and DNA
repair to maintain DNA integrity. When the DNA damage is too much and irreparable,
the cells undergo apoptosis (Zhang & Hunter, 2014). The dose-response results from Tier
2 indicated that AZD7762 at 1 and 10 M severely promoted granulosa cell apoptosis
(Figure 3.5 and 7). Previous studies demonstrated that global deletion of Chk2 does not
impair female mouse fertility (Bolcun-Filas et al., 2014; Hirao et al., 2002; Takai et al.,
2002). Moreover, our results indicated that BML-277, a specific checkpoint kinase
inhibitor targeting Chk2 but not Chk1 (Arienti et al., 2005), was not ovotoxic (Figure
3.7B and 7C), suggesting that the AZD7762-induced granulosa cell apoptosis was not
directly caused by its inhibitory effect on Chk2.
There is limited data regarding the role of Chk1 in ovarian follicle development
and survival because Chk1-deficiency is embryonically lethal during the periimplantation period (Liu et al., 2000; Takai et al., 2000). To determine whether the
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AZD7762-induced follicle death is caused by Chk1 inhibition, we tested three Chk1specific inhibitors and found that all three Chk1 inhibitors showed consistent
ovotoxicities to AZD7762 (Figure 3.7B and 7C), indicating that inhibition of Chk1 may
play essential roles in AZD7762-induced granulosa cell death. Since granulosa cells are
mitotically active during folliculogenesis, we speculate that the inhibition of Chk1 and
subsequent lack of Chk1-mediated cell cycle arrest and DNA repair, upon AZD7762 or
other Chk1 inhibitor treatment, result in excessive accumulation of DNA damage, which
triggers granulosa cell apoptosis. Chk1 has also been reported to regulate cell cycle
transition during normal mitotic division, such as the G1/S transition, S phase
progression, mitotic entry, and mitosis (Patil et al., 2013; Zhang & Hunter, 2014). As
granulosa cells are actively proliferating during folliculogenesis (Lu et al., 2005), it is
therefore also possible that the inhibition of Chk1 disrupts cell cycle transition during
granulosa cell proliferation, leading to apoptosis and the subsequent entire follicle atresia.
However, the underlying molecular mechanism of Chk1 inhibition and granulosa cell
apoptosis requires further investigations.
In addition to inhibiting Chk1, it is also possible that the granulosa cell apoptosis
induced by AZD7762 or other Chk1 inhibitors is caused by other off-target effects. For
example, rabusertib, a specific Chk1 inhibitor, has been found to not only inhibit the
phosphorylation of Chk1 at Ser296, the major mechanism to potentiate DNA damaging
agent-induced cancer cell death, but also directly result in cancer cell DNA damage and
apoptosis (van Harten et al., 2019; Wang et al., 2014). Moreover, although two Phase I
clinical trials demonstrated that AZD7762 could enhance the anticancer effect of two
widely used therapeutic chemicals, GEM and irinotecan (Ho et al., 2011; Sausville et al.,

34

2014), it was not advanced to Phase II stage due to the unintended cardiotoxicity (Ho et
al., 2011; Reichert et al., 2016; Sausville et al., 2014). It was hypothesized that AZD7762
may inhibit other non-checkpoint kinases or ATP-dependent non-kinase proteins to cause
cytotoxicities in cardiomyocytes (Ma et al., 2011; Manic et al., 2015), because another
Chk1 specific inhibitor, MK-8776, did not show cardiotoxicity (Daud et al., 2015).
Taken together, these results indicate that further studies are necessary to elucidate the
specific underlying molecular mechanism of Chk1 inhibitor-induced ovotoxicities.
Transgenic mice with conditional deletion of Chk1 in granulosa cells will help to confirm
the role of Chk1 in granulosa cell survival and proliferation.
GEM has been demonstrated to induce cancer cell DNA damage and activate
Chk1 but not Chk2 through phosphorylation (Isono et al., 2017; Morgan et al., 2006).
Activated Chk1 further phosphorylates Cdc25A to induce its proteolytic degradation and
results in CDK2 deactivation and cell cycle arrest at the S or G2 phase to allow for DNA
damage repair (Patil et al., 2013; Zhang & Hunter, 2014). When the levels of GEMinduced DNA damage are too high to be fully repaired, cancer cells undergo apoptosis. It
has been well demonstrated that co-treatment with AZD7762 abrogated Chk1-mediated
cell cycle arrest and potentiated GEM-induced cancer cell apoptosis (Isono et al., 2017;
Landau et al., 2012; Liu et al., 2017). For non-cancerous cells, it was expected that there
is a functional G1 checkpoint pathway allowing for DNA damage repair and cell survival
(Abraham, 2001; Zhang & Hunter, 2014), thus the co-treatment with AZD7762 will only
or primarily potentiate the cytotoxicities of DNA damaging agents on cancer cells
(Zabludoff et al., 2008). However, our results revealed that although AZD7762 at 0.1 M
alone did not induce follicle atresia as the higher concentrations at 1 and 10 M did, the
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co-treatment with AZD7762 at 0.1 M significantly enhanced GEM-induced growing
follicle death (Figure 3.9). These results suggest that the exacerbating effect of AZD7762
on GEM’s ovotoxicities might be primarily induced by inhibiting Chk1-mediated cell
cycle arrest and DNA repair. Interestingly, with respect to DOX which has been found to
damage growing follicles through inducing granulosa cell apoptosis (Xiao, Zhang, et al.,
2017a), the co-treatment with AZD7762 did not show any exacerbating effect (Figure
3.9). These results suggest that unlike the GEM-induced DNA damage and Chk1mediated cell cycle arrest or cell apoptosis, DOX may use different molecular
mechanisms to promote granulosa cell apoptosis in growing follicles.
The in vivo animal models in Tier 3 demonstrated that the clinically relevant
exposure level of AZD7762 promoted the death of growing follicles but not primordial
follicles (Figure 3.8), indicating that the dormant state of primordial follicles, particular
the mitotically inactive pregranulosa cells, are less sensitive to AZD7762. Similarly,
previous studies also found that several chemotherapeutic chemicals, such as
cyclophosphamide, primarily damaged growing follicles but not primordial follicles, and
the depletion or reduction of growing follicles could in turn overactivate primordial
follicles, exhausting the ovarian reserve (Gonfloni et al., 2009; Kim et al., 2013; Kim et
al., 2018; Nguyen et al., 2018). Therefore, although AZD7762 did not directly affect
primordial follicle survival, its damaging effect on growing follicles will also increase the
risk of premature ovarian failure, early menopause, and infertility through overactivating
primordial follicles and diminishing the ovarian reserve.
One of the limitations of our current study is that there is no liver metabolism in
the eIVFG system. However, some chemicals may require liver metabolic activation to

36

exhibit ovotoxicity or liver detoxification may inactivate the parent compound which is
ovotoxic. To resolve this issue, one potential approach is to include the metabolite(s) in
addition to the parental compound for in vitro compound exposure. A more encouraging
approach is to use the emerging microfluidic technology to interconnect in vitro cultured
ovarian tissues with liver organoids or cell lines to incorporate a more in vivo-like liver
metabolism and pharmacokinetics into ovotoxicity testing. For example, we recently
created a microfluidic platform that can integrate 2 or 5 different tissues together to study
the tissue-tissue communications (Xiao, Coppeta, et al., 2017). However, its high cost
and low-throughput properties limit its application in high-throughput ovotoxicity
screening, which requires further improvement. Another limitation here is that eIVFG
supports follicle growth starting from the primary or secondary stage. However, due to
the technical difficulties, it is challenging to individually culture primordial follicles in
vitro. Previous studies have cultured mouse neonatal whole ovaries or ovarian explants
(Kim et al., 2013), which is a good model to study the impact of pharmaceutical
compounds on primordial follicle survival and activation. Comparing to the in vivo
model, eIVFG is difficult to detect the ovotoxity of life-span exposure because we only
cultured the follicles for several days in a specific exposure window. For example, one
study found that the carcinogenic effects of aspartame are increased using the in vivo
model when the rats had a life-span exposure which begins during fetal life (Soffritti et
al., 2007).
In summary, our study demonstrates that eIVFG is a robust in vitro model for
testing the effects of pharmaceutical compounds on female ovarian functions and fertility.
The developed tiered ovotoxicity screening can efficiently and effectively help us
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identify and prioritize candidate compounds of high ovotoxicity concern for subsequent
more targeted, sophisticated, and mechanistic in vitro and in vivo ovotoxicity
assessments. In additional to pharmaceutical compounds, the developed tiered
ovotoxicity screening method also provides good models for investigating the impact of
environmental contaminants on female ovarian functions and fertility.
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